SGRY
INSIDER BUYSurgery Partners, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeSurgery Partners reported Q2 2026 revenue beat ($848.9M vs. $830M consensus) with same-facility revenue growth of 5.0%, but Adjusted EBITDA declined 3.0% year-over-year to $125.2M amid continued net losses. The company divested its Idaho Falls facilities for ~$795M (completed September 17), reducing 2026 guidance to $3.08–$3.18B, which triggered a 6% stock drop despite the balance-sheet improvement—signaling investor concern about reduced scale and operational momentum.
Red flags
- •Adjusted EBITDA declined 3.0% YoY despite revenue beat, indicating margin compression and operational deleverage
- •Company remains unprofitable with continued net losses despite asset sales and revenue growth
- •Stock down ~6% post-divestiture announcement despite cleaner balance sheet, suggesting investor skepticism about growth trajectory post-sale
- •Stock trading at $13.41 (early October 2026), near 52-week lows and below 200-day moving average, with weak longer-term returns despite analyst 'Buy' ratings
- •Guidance reduction following Idaho Falls sale represents reduced scale; new $3.08–$3.18B guidance implies meaningful revenue headwind for remainder of 2026
- •Zacks downgrade from 'Strong Buy' to 'Hold' in August, signaling analyst recalibration despite broader 'Moderate Buy' consensus
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Glenview Capital | SC 13G | NEW | 5.4% | +7.6% vs SPY +6.5% abs | 2026-10-13 | ↗ |